8. ハンチントン病 Huntington disease Clinical trials / Disease details
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02507284 (ClinicalTrials.gov) | May 10, 2016 | 22/7/2015 | Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease | An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD) | Irritable Mood;Huntington's Disease | Drug: SRX246;Drug: Placebo | Azevan Pharmaceuticals | National Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT Network | Completed | 18 Years | N/A | All | 106 | Phase 2 | United States |